Last edition
News about "Lupin"
Lupin Gets Approval from FDA for Abacavir, Dolutegravir and Lamivudine Tablets
Abacavir, Dolutegravir and Lamivudine Tablets for Oral Suspension, 60 mg/5 mg/30 mg, (RLD Triumeq PD) had an estimated annual sale of USD 1.3 million in the US.
Lupin | 06/12/2024 | By Aishwarya
Lupin Gets Tentative Approval from FDA for Sitagliptin and Metformin Hydrochloride Tablets
Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1000 mg are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Lupin | 02/12/2024 | By Aishwarya
Lupin Introduces Bumetanide Injection in US
Bumetanide Injection USP, is a generic equivalent of Bumex Injection, 0.25 mg/mL of Validus Pharmaceuticals, LLC., indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome.
Lupin | 22/11/2024 | By Aishwarya
Lupin Gets Tentative Approval from FDA for Raltegravir Tablets
Raltegravir Tablets USP, 600 mg are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients and in pediatric patients weighing at least 40 kg.
Lupin | 11/11/2024 | By Aishwarya
Lupin to Develop Inhalers with Near-Zero GWP Propellants
This initiative aims to provide patients with pressurised metered dose inhalers (pMDIs) that maintain the same efficacy and safety, while significantly reducing their environmental impact.
Lupin | 29/10/2024 | By Aishwarya | 272
Lupin Announces Appointment of Claus Jepsen as President-Global Specialty
Claus joins Lupin from Takeda Pharmaceuticals, where he led the Global Strategy for Rare Diseases.
Lupin | 22/10/2024 | By Aishwarya
Lupin Introduces First Generic Version of Pred Forte in US
Being the first generic to be approved and launched, the company is entitled to 180-day competitive generic therapy (CGT) exclusivity.
Lupin | 16/10/2024 | By Aishwarya
Lupin Signs Distribution Deal with Celnova for Orphan Drug NaMuscla
Celnova will commercialize NaMuscla in Argentina and Colombia, for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders.
Lupin | 30/09/2024 | By Aishwarya | 111
Lupin Gets FDA Approval for Bumetanide Injection
Bumetanide Injection USP, 1 mg/4 mL (0.25 mg/mL) Single-Dose Vials and 2.5 mg/10 mL (0.25 mg/mL) Multiple-Dose Vials are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome.
Lupin | 20/09/2024 | By Aishwarya
Lupin and Takeda to Commercialize Vonoprazan in India
Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India.
Lupin | 19/09/2024 | By Aishwarya | 151
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy